DXM bill ready for House debate
This article was originally published in The Tan Sheet
The Dextromethorphan Distribution Act, H.R. 1259, moves March 24 to the House calendar for floor debate (1"The Tan Sheet" March 9, 2009, p. 8). The Energy and Commerce Committee approved the bill March 4. The bill authored by Rep. Fred Upton, R-Mich., would curb bulk on-line sales of DXM, specifically targeting preventing abuse by teens. ... OMB puts a price on Upton bill: The Congressional Budget Office says in a March 20 report that H.R. 1259 would cost $1 million in 2010 to implement and $11 million between 2010 and 2014. The Energy and Commerce Committee ordered the report, which notes the bill potentially could impact direct spending and revenues, but estimates "any such effects would not be significant.
You may also be interested in...
Omnibus stalls: Congress March 6 extends a continuing resolution to fund most federal agencies through March 11 at fiscal 2008 levels while the House and Senate continue deliberating an omnibus package covering the rest of fiscal 2009. The previous continuing resolution expired March 6 (1"The Tan Sheet" Oct. 6, 2008, p. 9). The House Feb. 25 passed a $410 billion dollar omnibus package, H.R. 1105, including $2.6 billion for FDA, but the bill has stalled in the Senate (2"The Tan Sheet" March 2, 2009, p. 9). Votes are expected March 9 on Republican amendments and March 10 on the Senate's version of the omnibus covering federal agencies other than the departments of Defense and Homeland Security, which were funded in separate legislation Congress enacted in 2008
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.